Drug Discovery World

JANUARY 22, 2024

.” Andrea Bortolato , Director of Drug Discovery at SandboxAQ, will present: ‘Combining physics-based methods with AI solutions to maximise the probability of success and speed of drug discovery and development’. According to an article in Acta Pharmaceutica Sinica B , 90% of clinical drug development fails” 3.

Engineer 59

Engineer Immune Response Drugs Vaccination 59

Scienmag

OCTOBER 9, 2020

Findings could lay the foundation for the development of effective therapeutic and malaria vaccine strategies, which has largely been hindered by a lack of understanding of the host immune response Credit: Aissatou Diawara Abu Dhabi, UAE, October 9, 2020: The Plasmodium parasite, which transmits malaria to humans through infected mosquitos, triggers (..)

Immune Response 52

Immune Response Gene Research Vaccination 52

XTalks

SEPTEMBER 21, 2023

The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID).

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Scienmag

JUNE 27, 2021

The first human trial has shown no obvious side effects and a good immune response. Hiroshi Kiyono, CC BY 4.0 A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice. Researchers based […].

Vaccination 72

Vaccination Vaccine Immune Response Trials 72

The Pharma Data

MARCH 31, 2022

The trial aims to understand if different vaccine regimens – prototype and variant vaccines alone and in combinations – can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. Fauci, M.D. Nadine Rouphael, M.D., Source link: [link].

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

Scienmag

MARCH 19, 2021

Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer, study finds. MIT researchers have now developed a vaccination strategy that can create an army of T cells that are […].

Vaccination 48

Vaccination Vaccine Immune Response Development 48

Scienmag

JULY 6, 2021

Researchers at Karolinska Institutet in Sweden publish new findings in the journal Cancer Discovery showing how pharmacological activation of the protein p53 boosts the immune response against tumours. Given its ability to react […].

Immune Response 40

Immune Response Protein Development Research 40

pharmaphorum

SEPTEMBER 29, 2022

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain. The post FDA clears Dupixent as first drug for rare skin disorder appeared first on.

Drugs 69

Drugs Immune Response Allergies Sales 69

Scienmag

DECEMBER 22, 2020

Study provides insights that could inform vaccine timing and improve care BOSTON — Pregnant women may be especially vulnerable to developing more severe cases of COVID-19 following SARS-CoV-2 infection, but little is known about their anti-SARS-CoV-2 immune response or how it may affect their offspring.

Immune Response 40

Immune Response Antibody Vaccination Vaccine 40

Scienmag

DECEMBER 16, 2020

BOSTON — Understanding the body’s immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines. Scientists at the Ragon Institute of MGH, MIT and Harvard find that neutralizing antibody potency predicts severe or fatal COVID-19.

Antibody 40

Antibody Immune Response Scientist Vaccination 40

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The lead Principal Investigator for the INNOVATE trial is Dr. Pablo Tebas , Professor of Medicine at the Hospital of the University of Pennsylvania. .

DNA 40

DNA Vaccination Vaccine Immune Response 40

Bioengineer

JULY 15, 2021

“We’re excited–with such low doses of radiation, we didn’t expect the response to be so positive,” said lead author Ravi Patel, M.D., ” Immunotherapy has revolutionized cancer treatment by helping patients’ immune systems fight off cancer. Patel and senior author Zachary Morris, M.D.,

Medicine 52

Medicine Clinical Trials Clinical Trials Scientist 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults.

Vaccination 53

Vaccination Vaccine Research Trials 53

Pfizer

JULY 19, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. has a fever.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

The Pharma Data

NOVEMBER 17, 2020

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. This new study will complement Mymetics’ other preclinical Covid-19 studies that are ongoing at Baylor College of Medicine in Texas USA and the Helmholtz Center of Infection Research in Germany.

Vaccination 40

Vaccination Vaccine Containment Immune Response 40

Pfizer

JULY 26, 2022

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. has a fever.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

The Pharma Data

APRIL 28, 2021

Head of Global Development in Immunology and Inflammation at Sanofi. “ In addition , o ur expanded efforts in research and development in the immunology space , including rilzabrutinib , underscores our long-term commitment to addressing serious dermatological conditions with unmet patient needs. ”. Dupixent is approved in the U.S.

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

XTalks

MAY 17, 2024

Led by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), World AIDS Vaccine Day emphasizes the importance of awareness and education in the fight against HIV/AIDS. The Historical Quest for an HIV Vaccine The history of HIV/AIDS is one of the most dramatic narratives in the field of medicine.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

pharmaphorum

AUGUST 13, 2020

One Pfizer brand getting plenty of attention is Xeljanz, their blockbuster anti-JAK rheumatoid arthritis pill that could damp down the massive immune response that overwhelms some COVID-19 patients.

Branding 92

Branding Vaccination Vaccine Filler 92

Drug Discovery World

FEBRUARY 3, 2023

A research group from the National Institutes of Health has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. SUDV, identified in 1976, is one of the four viruses known to cause human Ebolavirus disease.

Vaccination 52

Vaccination Vaccine Genetic Engineering Protein 52

The Pharma Data

JULY 8, 2021

Tezepelumab is being developed by Amgen in collaboration with AstraZeneca. The FDA grants Priority Review to applications for medicines that offer significant advantages over available options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.(1) Reese, M.D.,

Allergies 52

Allergies Trials In-Vivo Medicine 52

Pfizer

JULY 8, 2022

Following a third dose in this age group , the vaccine was found to elicit a strong immune response, with a favorable safety profile similar to placebo. COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. NEW YORK and MAINZ, Germany, July 8, 2022 — Pfizer Inc.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

Scienmag

SEPTEMBER 15, 2020

Credit: Michigan State University Differences in biological sex can dictate lifelong disease patterns, says a new study by Michigan State University researchers that links connections between specific hormones present before and after birth with immune response and lifelong immunological disease development.

Hormones 78

Hormones Immune Response Development Research 78

Scienmag

FEBRUARY 18, 2021

Researchers at the Ragon Institute of MGH, MIT and Harvard and Massachusetts General Hospital show that levels of specific antibodies developed in the immune response may influence COVID-19 outcomes in both children and adults.

Antibody 74

Antibody Immune Response Development Research 74

Pfizer

JULY 8, 2022

Pfizer and BioNTech also filed these data with the European Medicines Agency (EMA) and other regulatory authorities around the world. COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. are immunocompromised or are on a medicine that affects the immune system.

FDA Approval 102

FDA Approval Vaccination Vaccine Clinical Trials 102

Scienmag

FEBRUARY 19, 2021

Preclinical tests at UAB last year showed potent systemic and mucosal immune responses in mice after a single intranasal dose. The vaccine candidate was developed by Maryland-based Altimmune Inc. Credit: UAB BIRMINGHAM, Ala. – The Altimmune Inc.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

NOVEMBER 9, 2020

9, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations compared to placebo in patients with severe asthma. THOUSAND OAKS, Calif. ,

Trials 52

Trials Production Sales Manufacturing 52

Drug Discovery World

AUGUST 1, 2023

In terms of partnerships and development , Orbit Discovery and start-up SanegeneBio have entered into a Master Service Agreement to identify tissue-specific delivery of a wide range of RNA therapeutics, as reported by DDW in January 2023. Over at UK biotech firm SynaptixBio, a company which secured £13.2

RNA 52

RNA Drugs Gene Silencing Vaccination 52

The Pharma Data

APRIL 27, 2021

General Medicines core assets grew 4.4%, while GBU sales were down 3.8%. Progress on implementation of the Corporate Social Responsibility strategy. Sanofi has become a member of the top five companies of the 2021 Access to Medicine index. General Medicines. General Medicines sales were down 3.8% Change at CER.

Sales 52

Sales Vaccination Vaccine Medicine 52

The Pharma Data

DECEMBER 21, 2020

The 48-week trial assessed the efficacy and safety of the potential new medicine tezepelumab compared to placebo in 150 severe asthma patients who required maintenance use of oral corticosteroids (OCS) on top of standard of care (SoC). executive vice president of Research and Development at Amgen. THOUSAND OAKS, Calif. , Reese , M.D.,

Trials 40

Trials Production Sales Manufacturing 40

The Pharma Data

FEBRUARY 8, 2021

General Medicines declined 7.5%, reflecting lower U.S. We bolstered our R&D pipeline with the completion of the Synthorx and Principia acquisitions, met several regulatory milestones to bring our important medicines to patients, and have seen several proofs of concept which reassure us about the priorities we chose. CHC down 3.0%

Sales 52

Sales Vaccination Vaccine Production 52

The Pharma Data

FEBRUARY 4, 2021

General Medicines declined 7.5%, reflecting lower U.S. We bolstered our R&D pipeline with the completion of the Synthorx and Principia acquisitions, met several regulatory milestones to bring our important medicines to patients, and have seen several proofs of concept which reassure us about the priorities we chose. CHC down 3.0%

Sales 52

Sales Vaccination Vaccine Production 52

The Pharma Data

OCTOBER 29, 2021

Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine authority, Zabdeno ® (Ad26.ZEBOV) ZEBOV) and Mvabea ® (MVA-BN-Filo), was well permitted and convinced a robust vulnerable response in both healthy grown-ups and grown-ups living with HIV. 115854), EBOVAC2 ( entitlement nr.

Immune Response 40

Immune Response Medicine Vaccination Vaccine 40

The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) Global Head, Janssen Research & Development, Johnson & Johnson. Additional follow-up with trial participants is currently underway.

Immune Response 52

Immune Response Medicine Vaccination Vaccine 52

Pfizer

NOVEMBER 2, 2022

The vaccine candidate combines Pfizer’s quadrivalent modRNA-based influenza vaccine candidate, qIRV (22/23), which is currently in Phase 3 clinical development , and Pfizer and BioNTech’s authorized Omicron-adapted bivalent COVID-19 BNT162b2 (Original/Omicron BA.4/BA.5) The companies will share the development costs. Ugur Sahin, M.D.,

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

The Pharma Data

MAY 13, 2021

The vaccine regimen, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) in collaboration with Bavarian Nordic A/S, is being donated to the WHO by Janssen for the purposes of the early access clinical program. Global Head, Global Public Health Research & Development, Johnson & Johnson. “We

Vaccination 52

Vaccination Vaccine Medicine Clinical Trials 52

The Pharma Data

JULY 6, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52